Literature DB >> 28490988

The role of SBRT in oligometastatic patients with liver metastases from breast cancer.

Marta Scorsetti1, Davide Franceschini1, Fiorenza De Rose1, Tiziana Comito1, Ciro Franzese1, Giovanna Masci2, Rosalba Torrisi2, Luca Viganò3, Guido Torzilli3.   

Abstract

Liver metastases from breast cancer are a common occurrence. Local ablative therapies are a promising therapeutic option for these patients, with the potential for a long term disease control in the setting of "oligometastatic patients". Identification of the perfect candidate for local approaches is still challenging and unclear. Stereotactic body radiation therapy (SBRT) is one of the most valuable local therapy, because of great efficiency, low morbidity and minimal invasiveness. In this paper, we reviewed the state of the art in the care of breast cancer patients with liver metastases, with a focus on SBRT.

Entities:  

Keywords:  Breast; Liver; Metastases; Radiotherapy; SBRT

Year:  2016        PMID: 28490988      PMCID: PMC5411907          DOI: 10.1016/j.rpor.2016.07.008

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  31 in total

1.  American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy.

Authors:  Louis Potters; Brian Kavanagh; James M Galvin; James M Hevezi; Nora A Janjan; David A Larson; Minesh P Mehta; Samuel Ryu; Michael Steinberg; Robert Timmerman; James S Welsh; Seth A Rosenthal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-01       Impact factor: 7.038

2.  Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial.

Authors:  Marta Scorsetti; Stefano Arcangeli; Angelo Tozzi; Tiziana Comito; Filippo Alongi; Pierina Navarria; Pietro Mancosu; Giacomo Reggiori; Antonella Fogliata; Guido Torzilli; Stefano Tomatis; Luca Cozzi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-02-20       Impact factor: 7.038

Review 3.  Metastatic colorectal cancer: is there one standard approach?

Authors:  Leonard B Saltz
Journal:  Oncology (Williston Park)       Date:  2005-08       Impact factor: 2.990

4.  Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer.

Authors:  Marta Scorsetti; Davide Franceschini; Fiorenza De Rose; Tiziana Comito; Elisa Villa; Cristina Iftode; Pierina Navarria; Giuseppe Roberto D'Agostino; Giovanna Masci; Rosalba Torrisi; Alberto Testori; Corrado Tinterri; Armando Santoro
Journal:  Breast       Date:  2016-01-03       Impact factor: 4.380

5.  Does Radiotherapy Have Curative Potential in Metastatic Patients? The Concept of Local Therapy in Oligometastatic Breast Cancer.

Authors:  Kathrin Dellas
Journal:  Breast Care (Basel)       Date:  2011-10-13       Impact factor: 2.860

6.  Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history.

Authors:  J Scheele; R Stangl; A Altendorf-Hofmann
Journal:  Br J Surg       Date:  1990-11       Impact factor: 6.939

7.  Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.

Authors:  Joseph K Salama; Michael D Hasselle; Steven J Chmura; Renuka Malik; Neil Mehta; Kamil M Yenice; Victoria M Villaflor; Walter M Stadler; Philip C Hoffman; Ezra E W Cohen; Philip P Connell; Daniel J Haraf; Everett E Vokes; Samuel Hellman; Ralph R Weichselbaum
Journal:  Cancer       Date:  2011-10-21       Impact factor: 6.860

8.  Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis.

Authors:  Daniel T Chang; Anand Swaminath; Margaret Kozak; Julie Weintraub; Albert C Koong; John Kim; Rob Dinniwell; James Brierley; Brian D Kavanagh; Laura A Dawson; Tracey E Schefter
Journal:  Cancer       Date:  2011-03-22       Impact factor: 6.860

Review 9.  The role of surgery and ablative radiotherapy in oligometastatic breast cancer.

Authors:  Joseph K Salama; Steven J Chmura
Journal:  Semin Oncol       Date:  2014-10-07       Impact factor: 4.929

10.  Actual 10-year survival after resection of colorectal liver metastases defines cure.

Authors:  James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

View more
  5 in total

1.  Editorial.

Authors:  Miquel Macià; Carmen Llacer-Moscardo
Journal:  Rep Pract Oncol Radiother       Date:  2016-10-15

2.  Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy.

Authors:  Barbara Alicja Jereczek-Fossa; Barbara Bortolato; Marianna Alessandra Gerardi; Samantha Dicuonzo; Virginia Maria Arienti; Stefania Berlinghieri; Stefano Bracelli; Michela Buglione; Mariangela Caputo; Gianpiero Catalano; Luigi Franco Cazzaniga; Luigi De Cicco; Nadia Di Muzio; Francesco Romeo Filippone; Andrei Fodor; Davide Franceschini; Paolo Frata; Stefania Gottardo; Giovanni Battista Ivaldi; Antonio Laudati; Stefano Maria Magrini; Elisa Mantero; Ilaria Meaglia; Sara Morlino; Mauro Palazzi; Fabio Piccoli; Paola Romanelli; Marta Scorsetti; Flavia Serafini; Luciano Scandolaro; Riccardo Valdagni; Roberto Orecchia; Paolo Antognoni
Journal:  Radiol Med       Date:  2018-12-15       Impact factor: 3.469

Review 3.  Treatment Strategies for Oligometastatic Breast Cancer.

Authors:  Eric G Nesbit; Eric D Donnelly; Jonathan B Strauss
Journal:  Curr Treat Options Oncol       Date:  2021-08-23

4.  Long-term survival results after treatment for oligometastatic brain disease.

Authors:  Carsten Nieder; Mandy Hintz; Ilinca Popp; Angelika Bilger; Anca L Grosu
Journal:  Rep Pract Oncol Radiother       Date:  2020-03-04

Review 5.  Stereotactic body radiotherapy (SBRT) for oligo-metastatic liver metastases from breast cancer, as an effective and safe alternative to surgery: a review.

Authors:  Shuri Aoki; Hideomi Yamashita; Osamu Abe; Keiichi Nakagawa
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.